Trial Profile
An Open-label, Flexibly-dosed, Multicenter, Extension Study of Dasotraline to Evaluate Long-term Safety and Tolerability in Adults With Binge-eating Disorder
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Aug 2020
Price :
$35
*
At a glance
- Drugs Dasotraline (Primary)
- Indications Binge-eating disorder
- Focus Adverse reactions
- Sponsors Sunovion Pharmaceuticals
- 30 Jul 2019 Results presented in a Sunovion Pharmaceuticals media release.
- 01 Jul 2019 Status changed from active, no longer recruiting to completed.
- 17 Dec 2018 Planned End Date changed from 30 Nov 2019 to 30 Jun 2019.